Literature DB >> 15155183

Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis.

Joseph J Dajcs1, Brett A Thibodeaux, Mary E Marquart, Dalia O Girgis, Mullika Traidej, Richard J O'Callaghan.   

Abstract

The purpose of this study was to quantitatively compare, in a rabbit keratitis model, the levels of effectiveness of moxifloxacin, levofloxacin, and ciprofloxacin for the treatment of Staphylococcus aureus isolates of diverse antibiotic susceptibilities. Rabbit eyes were intrastromally injected with approximately 100 CFU of methicillin-sensitive or methicillin-resistant S. aureus (MSSA or MRSA, respectively) organisms that were either sensitive or resistant to ofloxacin. One drop of moxifloxacin (0.5%), levofloxacin (0.5%), or ciprofloxacin (0.3%) was topically applied hourly from 4 to 9 (early) or 10 to 15 (late) h postinfection. At 1 h after cessation of therapy, the corneas were harvested, and the number of CFU per cornea was determined. For the ofloxacin-sensitive strains, early treatment of MSSA or MRSA with moxifloxacin, levofloxacin, or ciprofloxacin produced approximately a 5-log decrease in CFU per cornea relative to that in untreated eyes (P </= 0.0001). For late therapy of ofloxacin-sensitive strains, moxifloxacin, levofloxacin, and ciprofloxacin produced approximately 5-, 4-, and 2- to 3-log reductions in CFU per cornea, respectively (P </= 0.0001). Early treatment of the ofloxacin-resistant strains with either moxifloxacin or levofloxacin produced a >/=4-log or >/=3-log decrease, respectively, in the MSSA or MRSA strains (P </= 0.0001), whereas ciprofloxacin treatment produced a 1-log decrease in CFU per cornea relative to that in untreated eyes (P = 0.1540). For late treatment of ofloxacin-resistant strains, levofloxacin and ciprofloxacin failed to significantly reduce the number of CFU per cornea (P >/= 0.3627), whereas moxifloxacin produced a significant reduction in CFU per cornea of approximately 1 log (P </= 0.0194). Therefore, for three of the four treatments tested, moxifloxacin demonstrated greater effectiveness than either levofloxacin or ciprofloxacin.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15155183      PMCID: PMC415620          DOI: 10.1128/AAC.48.6.1948-1952.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  In vitro activity of BAY 12-8039, a new fluoroquinolone, against species representative of respiratory tract pathogens.

Authors:  M Souli; C B Wennersten; G M Eliopoulos
Journal:  Int J Antimicrob Agents       Date:  1998-04       Impact factor: 5.283

2.  Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin.

Authors:  K Hiramatsu; N Aritaka; H Hanaki; S Kawasaki; Y Hosoda; S Hori; Y Fukuchi; I Kobayashi
Journal:  Lancet       Date:  1997-12-06       Impact factor: 79.321

3.  Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model.

Authors:  P D Lister
Journal:  Clin Infect Dis       Date:  2001-03-15       Impact factor: 9.079

4.  Community strain of methicillin-resistant Staphylococcus aureus involved in a hospital outbreak.

Authors:  F G O'Brien; J W Pearman; M Gracey; T V Riley; W B Grubb
Journal:  J Clin Microbiol       Date:  1999-09       Impact factor: 5.948

5.  Lysostaphin treatment of methicillin-resistant Staphylococcus aureus keratitis in the rabbit.

Authors:  J J Dajcs; E B Hume; J M Moreau; A R Caballero; B M Cannon; R J O'Callaghan
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-05       Impact factor: 4.799

6.  Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review.

Authors:  M H Goldstein; R P Kowalski; Y J Gordon
Journal:  Ophthalmology       Date:  1999-07       Impact factor: 12.079

7.  Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones.

Authors:  G Alexandrakis; E C Alfonso; D Miller
Journal:  Ophthalmology       Date:  2000-08       Impact factor: 12.079

8.  Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases.

Authors:  F Blanche; B Cameron; F X Bernard; L Maton; B Manse; L Ferrero; N Ratet; C Lecoq; A Goniot; D Bisch; J Crouzet
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

9.  Specific roles of alpha-toxin and beta-toxin during Staphylococcus aureus corneal infection.

Authors:  R J O'Callaghan; M C Callegan; J M Moreau; L C Green; T J Foster; O M Hartford; L S Engel; J M Hill
Journal:  Infect Immun       Date:  1997-05       Impact factor: 3.441

10.  The comparative antimicrobial activity of levofloxacin tested against 350 clinical isolates of streptococci.

Authors:  D J Biedenbach; R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  1996-05       Impact factor: 2.803

View more
  12 in total

1.  Topical levofloxacin 1.5% overcomes in vitro resistance in rabbit keratitis models.

Authors:  Regis P Kowalski; Eric G Romanowski; Francis S Mah; Robert M Q Shanks; Y J Gordon
Journal:  Acta Ophthalmol       Date:  2010-04-23       Impact factor: 3.761

2.  Resistance pattern of ciprofloxacin against different pathogens.

Authors:  Syeda Q Ali; Ale Zehra; Baquar S Naqvi; Shahjahan Shah; Rabia Bushra
Journal:  Oman Med J       Date:  2010-10

3.  Effect of formulation factors on in vitro permeation of moxifloxacin from aqueous drops through excised goat, sheep, and buffalo corneas.

Authors:  Pravin Kondiba Pawar; Dipak K Majumdar
Journal:  AAPS PharmSciTech       Date:  2006-02-10       Impact factor: 3.246

4.  Dexamethasone as adjuvant therapy to moxifloxacin attenuates valve destruction in experimental aortic valve endocarditis due to Staphylococcus aureus.

Authors:  Ioannis Skiadas; Angelos Pefanis; Apostolos Papalois; Aspasia Kyroudi; Helen Triantafyllidi; Thomas Tsaganos; Helen Giamarellou
Journal:  Antimicrob Agents Chemother       Date:  2007-06-11       Impact factor: 5.191

5.  Postantibiotic effects and bactericidal activities of levofloxacin and gatifloxacin at concentrations simulating those of topical ophthalmic administration against fluoroquinolone-resistant and fluoroquinolone-sensitive methicillin-resistant Staphylococcus aureus strains.

Authors:  Saichi Hoshi; Ken Kikuchi; Takashi Sasaki; Chie Sotozono; Shigeru Kinoshita; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2008-05-19       Impact factor: 5.191

Review 6.  Animal models of bacterial keratitis.

Authors:  Mary E Marquart
Journal:  J Biomed Biotechnol       Date:  2011-01-04

7.  Evaluation of the levofloxacin release characters from a rabbit foldable capsular vitreous body.

Authors:  Zhaoxin Jiang; Ting Wang; Biyan Pan; Zhiyong Xie; Peijuan Wang; Yaqin Liu; Qianying Gao
Journal:  Int J Nanomedicine       Date:  2011-12-30

8.  Preparation and In Vitro/Ex Vivo Evaluation of Moxifloxacin-Loaded PLGA Nanosuspensions for Ophthalmic Application.

Authors:  Meetali Mudgil; Pravin K Pawar
Journal:  Sci Pharm       Date:  2013-02-04

9.  Efficacy of Caltropis procera and Ficus sycomorus extracts in treating MRSA (methicillin-resistant Staphylococcus aureus)-keratitis in rabbit.

Authors:  Waiel F Sayed; Wesam M A Salem; Mohie A M Haridy; Ne'mat H Hassan
Journal:  EXCLI J       Date:  2015-06-16       Impact factor: 4.068

Review 10.  Oral antibiotic therapy for the treatment of infective endocarditis: a systematic review.

Authors:  Awad Al-Omari; D William Cameron; Craig Lee; Vicente F Corrales-Medina
Journal:  BMC Infect Dis       Date:  2014-03-13       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.